CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc., announced today new preclinical data confirming ghrelin antagonism as a potential method for regulating metabolism, decreasing body weight and managing blood glucose. The data were presented in poster sessions during ENDO 07, The Endocrine Society’s 89th Annual Meeting, being held in Toronto, Canada. Elixir is focused on the development of drugs to treat and prevent metabolic disease, as well as prevent age-related diseases, based on targets identified in the pathways regulating aging.
